Active, not recruitingPhase 2NCT03971461
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
Studying Meningioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NYU Langone Health
- Principal Investigator
- Erik Sulman, MD, MD, PHDNew York Langone Health
- Intervention
- Lutathera(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2027
Study locations (2)
- NYU Langone Health, New York, New York, United States
- Cleveland Clinic, Cleveland, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03971461 on ClinicalTrials.govOther trials for Meningioma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07413796Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted SuturesMedical University of Warsaw
- RECRUITINGPHASE2NCT06955169Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior TreatmentRTOG Foundation, Inc.
- RECRUITINGPHASE1, PHASE2NCT07150806RYZ101 for the Treatment of Progressive or Recurrent Intracranial MeningiomaJoshua Palmer
- RECRUITINGNANCT06831461Proton Versus Photon Radiotherapy in Adults With Primary Brain TumorsTata Memorial Centre
- RECRUITINGNCT07044076Translation and Validation of the MQOL Self-questionnaire Into French for Assessing Quality of Life in Patients With MeningiomasCentre Hospitalier St Anne
- RECRUITINGPHASE2NCT05940493Abemaciclib in Newly Diagnosed Meningioma PatientsNader Sanai
- RECRUITINGNCT06874426The Impact of Endoscopic Endonasal Skull Base Surgery on OlfactionUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGPHASE2NCT06326190177Lu-DOTATATE for Recurrent MeningiomaEuropean Organisation for Research and Treatment of Cancer - EORTC